The University of South Australia has made a groundbreaking discovery that could revolutionize the treatment of Parkinson’s disease. Scientists have developed a long-acting injectable formulation that delivers a steady dose of levodopa and carbidopa over an entire week, potentially replacing the need for multiple daily tablets.

Parkinson’s disease is the second most common neurological disorder, affecting more than 8.5 million people worldwide. Currently, there is no cure, and symptoms such as tremors, rigidity, and slow movement are managed with oral medications that must be taken several times a day. The frequent dosing can be a burden, especially for elderly patients or those with swallowing difficulties, leading to inconsistent medication levels, more side effects, and reduced effectiveness.

The newly developed injectable gel combines an FDA-approved biodegradable polymer PLGA with Eudragit L-100, a pH-sensitive polymer, to achieve a controlled and sustained drug release. The system can be tuned to release drugs over a period ranging from a few days to several weeks depending on therapeutic needs.

Lead researcher Professor Sanjay Garg says the weekly injection could significantly improve treatment outcomes and patient adherence. “Our goal was to create a formulation that simplifies treatment, improves patient compliance, and maintains consistent therapeutic levels of medication. This weekly injection could be a game-changer for Parkinson’s care.”

UniSA PhD student Deepa Nakmode adds, “After years of focused research, it’s incredibly rewarding to see our innovation in long-acting injectables for Parkinson’s disease reach this stage. Our invention has now been filed for an Australian patent.”

The implications of this research are profound, and the technology could also be adapted for other chronic conditions such as cancer, diabetes, neurodegenerative disorders, pain management, and chronic infections that require long-term drug delivery.

UniSA scientists hope to start clinical trials in the near future and are exploring commercialisation opportunities. With this breakthrough, patients with Parkinson’s disease may soon have a more convenient and effective treatment option available, leading to improved quality of life and reduced burden on caregivers.

Breaking Ground: Tirzepatide Shows Promise in Reducing Obesity-Associated Breast Cancer Growth

A groundbreaking study presented at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, has shed light on the potential benefits of tirzepatide, a medication used to treat diabetes and obesity, in reducing breast cancer growth associated with obesity. The research, conducted by a team led by Drs. Erin Giles and Kanakadurga Singer at the University of Michigan, reveals that tirzepatide not only reduces body weight but also shrinks tumors in mice.

Obesity is a significant risk factor for breast cancer, and existing research has shown that individuals with obesity tend to have worse outcomes compared to those without. While traditional weight loss methods can improve outcomes, they often come with challenges. The study’s findings suggest that tirzepatide, which targets GLP-1 and GIP receptors, may be a promising alternative.

The researchers conducted their study on 16 mice fed a high-fat diet to induce obesity. They found that the anti-obesity medication reduced body weight and body fat by approximately 20%, primarily due to a loss of adipose mass. More remarkably, they discovered that tumor volume was significantly correlated with body weight, total adipose mass, and liver fat storage.

The preliminary results suggest that tirzepatide may have a beneficial impact on breast cancer outcomes. However, it is essential to note that these findings are still in the early stages of research and require further investigation. Ongoing studies are being conducted in collaboration with Dr. Steve Hursting’s lab at the University of North Carolina at Chapel Hill to separate the weight loss from the tumor-specific effects of tirzepatide.

While more research is needed, the potential benefits of tirzepatide in reducing obesity-associated breast cancer growth are exciting and worthy of further exploration. As researchers continue to study this medication, they may uncover new avenues for improving outcomes for individuals with breast cancer and obesity.

The article reveals a surprising truth: high blood sugar levels can have a significant impact on men’s sexual health, even if they are not diabetic. A recent study presented at the Endocrine Society’s annual meeting in San Francisco found that modest increases in blood sugar were the primary drivers of changes in the reproductive systems and sexual functioning of aging men.

According to Dr. Michael Zitzmann, professor and doctor of medicine at University Hospital in Muenster, Germany, “Our research indicates that these changes more closely correlate with modest increases in blood sugar and other metabolic changes.” This means that men can take proactive steps to preserve or revive their reproductive health through lifestyle choices and medical interventions.

The study followed a group of 200 healthy men aged 18-85 over six years. Researchers studied the participants’ semen and hormonal profiles, erectile functioning, and metabolic health (BMI and blood sugar levels). The findings showed that:

* Hormone levels and semen parameters remained largely within normal ranges.
* Sperm movement and erectile function declined in men with minimally elevated blood sugar levels (below 6.5% HbA1c diabetes threshold).
* Testosterone levels did not directly impact erectile function but correlated with participants’ libido assessment.

The study’s conclusions are hopeful: “We’re now aware that it’s within our power to retain sexual and reproductive well-being in men, even as they age.” This research was conducted as part of the FAME 2.0 study, providing valuable insights for healthcare professionals and patients to formulate effective male sexual health maintenance plans.